Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Designated Drug Use Investigation 1 of Follistim Injection (Study P06130)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00920361
Recruitment Status : Completed
First Posted : June 15, 2009
Last Update Posted : February 5, 2015
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:

To evaluate dosage and administration method, efficacy and safety of Puregon and the relationship between background factors of patients and dose and administration method.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

Condition or disease Intervention/treatment
Fertilization in Vitro Drug: Follitropin beta

Layout table for study information
Study Type : Observational
Actual Enrollment : 1664 participants
Time Perspective: Prospective
Official Title: Designated Drug Use Investigation 1 of Follistim Injection
Study Start Date : November 2005
Actual Primary Completion Date : March 2009
Actual Study Completion Date : March 2009

Group/Cohort Intervention/treatment
Patients who underwent IVF
Drug: Follitropin beta
Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.

Primary Outcome Measures :
  1. Number of retrieved oocytes [ Time Frame: 2 months, from initiation of treatment to confirmation of pregnancy. ]

Secondary Outcome Measures :
  1. Pregnancy outcome [ Time Frame: 2 months, from initiation of treatment to confirmation of pregnancy. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Japanese 1100 patients

Inclusion Criteria:

  • Patients who underwent IVF

Exclusion Criteria:

  • Patients with tumors of ovary, breast, uterus, pituitary or hypothalamus
  • Pregnant or possible pregnant women, or lactating women
  • Patients with undiagnosed atypical vaginal bleeding
  • Patients with a history of hypersensitivity to any of the ingredients of this product.
  • Patients with ovarian cysts or enlarged ovaries, not related to polycystic ovarian disease

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00920361    
Other Study ID Numbers: P06130
First Posted: June 15, 2009    Key Record Dates
Last Update Posted: February 5, 2015
Last Verified: February 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Follicle Stimulating Hormone
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs